Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Firat, Elke  [Clear All Filters]
2024
Onyshchenko K, Luo R, Rao X, Zhang X, Gaedicke S, Grosu A-L, Firat E, Niedermann G. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models. Theranostics. 2024;14(6):2573-2588.
2023
Onyshchenko K, Luo R, Guffart E, Gaedicke S, Grosu A-L, Firat E, Niedermann G. Expansion of circulating stem-like CD8 T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice. Nat Commun. 2023;14(1):2087.
2022
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Schumacher A, Lagies S, Frey A, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022:215697.
2021
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Heitzler A, Lagies S, Frey A, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2021.
2015
Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schueler J, Wider D, et al. Effective eradication of glioblastoma stem cells by local application of an AC133/CD133-specific T cell-engaging antibody and CD8 T cells. Cancer Res. 2015.
2014
Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2014.